Shuttle Pharmaceuticals Holdings, Inc. Logo

Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):
US8256933024
LEI:
Country:
United States of America
Address:
401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENERON PHARMACEUTICALS, INC. Logo
A biotech firm inventing, developing, and commercializing medicines for serious diseases.
United States of America
REGN
REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.